EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Highlights in IO: next-generation CAR-T therapy for glioblastoma

Junya Yamaguchi, Hideho Okada

Journal for ImmunoTherapy of Cancer · 2026-04 · 14 (4) · e014670

DOI: 10.1136/jitc-2025-014670 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 01.04.2026. Verfasst von Junya Yamaguchi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Glioblastoma, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Brain Neoplasms. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past few years, outcomes and findings from several phase 1 clinical trials evaluating chimeric antigen receptor (CAR)-T cell therapies for glioblastoma (GBM) have been reported. For CAR-T cell therapy to succeed in GBM, several challenges must be overcome, including the immunosuppressive microenvironment (immunosuppressive cells, hypoxia, and metabolic constraints), antigen heterogeneity, and the anatomically isolated environment. To address these challenges, next-generation CAR-T cells—those engineered with additional functionalities—have been developed, and phase 1 clinical trials evaluating these next-generation CAR-T therapies for GBM have now been initiated. The development of CAR-T therapy for GBM has entered a new chapter. To date, the antitumor efficacy of CAR-T therapies still needs to be improved, and the high frequency of neurotoxicity remains a major issue that needs to be addressed; however, there is a growing anticipation that next-generation CAR-T therapies may provide clinical benefit to patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaImmunotherapy, AdoptiveReceptors, Chimeric AntigenBrain NeoplasmsT-LymphocytesReceptors, Antigen, T-CellHumansAnimals

Stichwörter der Autor:innen

Adoptive cell therapy - ACTCentral Nervous System CancerChimeric antigen receptor - CARImmunotherapy

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
  • Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA hideho.okada@ucsf.edu.
  • Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.

Förderung

  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Yamaguchi, J., & Okada, H. (2026). Highlights in IO: next-generation CAR-T therapy for glioblastoma. Journal for ImmunoTherapy of Cancer, 14(4), e014670. https://doi.org/10.1136/jitc-2025-014670

Vancouver

Yamaguchi J, Okada H. Highlights in IO: next-generation CAR-T therapy for glioblastoma. Journal for ImmunoTherapy of Cancer. 2026;14(4):e014670. doi:10.1136/jitc-2025-014670

BibTeX
@article{Yamaguchi2026,
  author = {Yamaguchi, Junya and Okada, Hideho},
  title = {Highlights in IO: next-generation CAR-T therapy for glioblastoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {4},
  pages = {e014670},
  doi = {10.1136/jitc-2025-014670}
}
Kostenlos starten →